The Cardiac Research Program offers a new five-year clinical trial for treating hypercholesterolemia.
FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) involves a PCSK9 inhibitor vs. placebo subcutaneously selfinjected biweekly, plus maximally tolerated Atorvastatin.
Qualified participants are individuals age 40-85 who experienced a myocardial infarction (MI) or stroke within the last five years with either:
- One major risk factor (Type 2 diabetes, over age 65, another MI or stroke in the last six months)
- Two minor risk factors (elevated lipid levels, hypertension, elevated blood sugar)
For more information, contact Valerie Assalone, RN, CCRP (ext. 3193) or Tina Cullen, RN, CCRC (ext. 4849).